Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane - Blackwell, K L; Miles, D; Gianni, L (J Clin Oncol, 2012)
Abstr. LBA1